Sapient Capital LLC Sells 4,546 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Sapient Capital LLC reduced its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 57.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,358 shares of the company’s stock after selling 4,546 shares during the quarter. Sapient Capital LLC’s holdings in TransMedics Group were worth $209,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Clear Creek Financial Management LLC bought a new position in shares of TransMedics Group during the 4th quarter worth $352,000. State of Alaska Department of Revenue bought a new position in TransMedics Group during the 3rd quarter worth about $2,560,000. Vaughan Nelson Investment Management L.P. increased its position in TransMedics Group by 9.9% during the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock valued at $22,547,000 after purchasing an additional 32,605 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of TransMedics Group by 2.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock valued at $42,656,000 after purchasing an additional 6,634 shares in the last quarter. Finally, Zacks Investment Management purchased a new stake in shares of TransMedics Group in the 3rd quarter worth approximately $1,607,000. 99.67% of the stock is owned by institutional investors.

TransMedics Group Stock Performance

Shares of TMDX opened at $69.52 on Thursday. The stock has a 50-day moving average of $65.75 and a two-hundred day moving average of $107.98. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The stock has a market cap of $2.33 billion, a P/E ratio of 73.96 and a beta of 2.12. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37.

Insider Buying and Selling

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. This trade represents a 4.94 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 7.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TMDX. JPMorgan Chase & Co. reissued a “neutral” rating and set a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a report on Wednesday, February 5th. Robert W. Baird decreased their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Canaccord Genuity Group cut their target price on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Finally, Oppenheimer reissued an “outperform” rating and set a $125.00 price target on shares of TransMedics Group in a research report on Tuesday, December 3rd. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.